152 related articles for article (PubMed ID: 6429046)
21. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
Collins MS; Roby RE
Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
[TBL] [Abstract][Full Text] [Related]
22. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
Matthews-Greer JM; Gilleland HE
J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.
Cryz SJ; Cross AS; Sadoff JC; Fürer E
Infect Immun; 1990 Feb; 58(2):373-7. PubMed ID: 2105272
[TBL] [Abstract][Full Text] [Related]
24. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa.
Markham RB; Pier GB; Schreiber JR
J Immunol; 1991 Jan; 146(1):316-20. PubMed ID: 1898604
[TBL] [Abstract][Full Text] [Related]
25. A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides.
Yokota S; Ohtsuka H; Kohzuki T; Noguchi H
FEMS Immunol Med Microbiol; 1996 May; 14(1):31-8. PubMed ID: 8804973
[TBL] [Abstract][Full Text] [Related]
26. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
27. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
29. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to Pseudomonas aeruginosa.
Schreiber JR; Patawaran M; Tosi M; Lennon J; Pier GB
J Immunol; 1990 Feb; 144(3):1023-9. PubMed ID: 2104908
[TBL] [Abstract][Full Text] [Related]
30. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
31. Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine.
Pier GB; Markham RB
J Immunol; 1982 May; 128(5):2121-5. PubMed ID: 6174622
[TBL] [Abstract][Full Text] [Related]
32. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.
Pollack M; Pier GB; Prescott RK
Infect Immun; 1984 Feb; 43(2):759-60. PubMed ID: 6420347
[TBL] [Abstract][Full Text] [Related]
33. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
Lieberman MM; McKissock DC; Wright GL
Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
[TBL] [Abstract][Full Text] [Related]
34. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.
Pier GB; Pollack M
Infect Immun; 1989 Feb; 57(2):426-31. PubMed ID: 2492260
[TBL] [Abstract][Full Text] [Related]
35. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
[TBL] [Abstract][Full Text] [Related]
36. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides.
Lang AB; Fürer E; Schürch U; Cross AS; Larrick JW; Cryz SJ
Dev Biol Stand; 1990; 71():121-6. PubMed ID: 1698165
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
Schreiber JR; Dahlhauser P
Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
[TBL] [Abstract][Full Text] [Related]
38. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
[TBL] [Abstract][Full Text] [Related]
39. [Immunologic study of artificial complex antigens obtained from P. aeruginosa lipopolysaccharides].
Edvabnaia LS; Stanislavskiĭ ES; Kolker II; Grishina IA; Zarubina EK
Zh Mikrobiol Epidemiol Immunobiol; 1979 Sep; (9):36-41. PubMed ID: 115186
[TBL] [Abstract][Full Text] [Related]
40. T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice.
Powderly WG; Pier GB; Markham RB
J Clin Invest; 1986 Aug; 78(2):375-80. PubMed ID: 2426306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
